Understanding the human immune system and combating diseases like cancer can be complex. In the fight against cancer, what if artificial intelligence could design a drug that helps solve one of the biggest challenges in immunotherapy – safely harnessing the power of IL-2?
The currently approved form of recombinant human IL-2 requires high doses that can be toxic and lead to cytokine storms as well as increased risk of pulmonary edema and blood vessel leakage. Newer generation IL-2 mimetics that are not yet approved can also create a negative feedback loop by triggering the secretion of more IL-2, which can lead to the expansion of regulatory T cells that suppress the very immune response the cancer treatment was meant to activate. Addressing these complexities requires IL-2 regulation, precision and innovation. That’s where Aulos comes in.